急性低氧性呼吸衰竭氧疗研究进展

段永博1, 祁宏志2, 宋昱静2, 阎文军1

【作者机构】 1兰州大学第一临床医学院; 2甘肃中医药大学第一临床医学院
【分 类 号】 R563
【基    金】 甘肃省联合科研基金重点项目(25JRRA1199)。
全文 参考文献 出版信息
急性低氧性呼吸衰竭氧疗研究进展

急性低氧性呼吸衰竭氧疗研究进展

段永博1 祁宏志2 宋昱静2 阎文军1▲

1.兰州大学第一临床医学院,甘肃兰州 730000;2.甘肃中医药大学第一临床医学院,甘肃兰州 730000

[摘要] 急性低氧性呼吸衰竭(AHRF)是临床常见的危重症,其病理生理机制复杂,病死率高。近年来,氧疗技术的创新与优化可显著改善AHRF患者的临床预后。本文系统综述经鼻高流量氧疗、无创正压通气和有创机械通气等主要氧疗方式的研究进展,重点分析各类技术的适应证、临床优势及潜在风险。同时,探讨呼吸频率氧合指数在疗效评估中的应用价值,以及俯卧位通气、闭环控制系统和人工智能等新兴技术在精准氧疗中的发展前景。通过整合现有证据,旨在为临床医师制订个体化氧疗方案提供循证依据,并指出今后研究需要关注的技术创新方向与临床转化挑战。

[关键词] 急性低氧性呼吸衰竭;无创氧疗;经鼻高流量氧疗;精准氧疗;人工智能

急性低氧性呼吸衰竭(acute hypoxemic respiratory failure,AHRF)是由多种病因引起的以血氧水平显著下降和组织缺氧为特征的急危重症,其病理生理过程涉及肺部炎症性水肿、通气丧失和呼吸驱动增加等改变。研究显示,AHRF患者约占全球重症监护病房入院患者中的32%,多需长期住院,预后不良[1]。在最严重的情况下(氧合指数<100 mmHg,1 mmHg=0.133 kPa),医院死亡率可达40%,严重威胁患者生命安全[2-3]。2019年全球新型冠状病毒感染疫情进一步增加AHRF的发生和临床负担[4]。AHRF病情进展迅速,患者需要及时且有效的氧合支持。因此AHRF的氧疗研究已成为研究热点。

1 AHRF的定义与病因

AHRF是指呼吸系统无法有效进行气体交换,导致氧合功能障碍,最新专家共识中的诊断标准为动脉血氧分压<60 mmHg,或氧合指数 ≤300 mmHg,或血氧饱和度<90%[5]。临床表现以呼吸急促、呼吸困难、发绀及辅助呼吸肌参与呼吸为主[6]。病因涵盖肺炎、急性呼吸窘迫综合征、肺水肿、重度哮喘、肺栓塞等,其中肺炎最常见,而新型冠状病毒感染成为近年来的重要病因之一[7]。AHRF不包括由心源性肺水肿和慢性肺部疾病急性加重导致的低氧血症,也不涉及急性高碳酸血症性呼吸衰竭(Ⅱ型呼吸衰竭),后者以通气功能障碍为主。

2 AHRF常用的氧疗技术

2.1 有创机械通气(invasive mechanical ventilation,IMV)

IMV通过气管插管连接机械呼吸机,为患者提供精确的氧气供给和压力支持,以维持有效的气体交换。IMV能改善AHRF患者的氧合状况,减轻呼吸肌的负担,并稳定血液气体参数,从而缓解因低氧引起的全身症状[8]。

在需要长时间使用的情况下,AHRF患者接受IMV,整体死亡率较高[9]。IMV的使用可引发呼吸机相关肺炎、气道损伤、感染、气胸及患者-呼吸机不同步等并发症,易对患者造成较严重的损伤[10-11]。研究显示,初始机械通气压力设置与AHRF患者入住重症监护病房后180 d死亡率呈显著正相关,尤其当初始机械通气压力>12 cmH2O[12]。IMV开始后24 h内暴露于高机械通气压力与AHRF患者重症监护病房死亡率升高相关[13]。但此试验未探索IMV的安全阈值压力,因此在IMV启动时降低机械通气压力可能是一种改善预后的策略,值得在临床试验中进一步探索。

鉴于IMV的这些缺点和风险,指南建议在临床上优先考虑无创氧疗以避免或延缓机械通气的使用,IMV通常作为AHRF的最后手段使用[14]。

2.2 鼻导管给氧

鼻导管给氧是一种简便易行的常用氧疗方式,适用于轻度低氧患者。鼻导管给氧的设备简单易操作,患者能在接受治疗时保持一定的舒适度,不影响说话和进食,因此具有较高的患者依从性。

然而,由于鼻导管给氧的流速通常为1~6 L/min,其提供的氧浓度和流量较低,难以满足重症AHRF患者对高氧浓度的需求[15]。在处理严重低氧症状时,鼻导管给氧常无法提供足够的氧合支持。

2.3 经鼻高流量氧疗(high-flow nasal oxygen therapy,HFNO)

2.3.1 HFNO的生理效应和临床应用 HFNO是一种通过患者的鼻腔以>15 L/min的高流量供氧的方法。该方法由空气/氧气混合器、主动加湿器、单加热回路和鼻导管组成,能提供高于常规吸气流量的流速,并稳定地输送氧气至肺泡。根据2020年的临床实践指南和2024年的会议共识,HFNO被推荐为AHRF的首选氧疗手段[5,14]。研究显示,HFNO可在保持自主呼吸的同时,产生低水平的持续气道正压,有利于鼻咽死腔的冲刷,降低呼吸功,防止肺不张和支气管痉挛[16-18]。HFNO还可促进自主呼吸,避免患者疲劳,降低患者自致肺损伤的风险[19-21]。与常规氧疗相比,使用HFNO治疗的严重AHRF患者气管插管的需要显著降低,机械通气支持的需求降低和临床恢复时间缩短[22-23]。Frat等[24]研究显示,HFNO可降低AHRF患者90 d死亡率。

2.3.2 HFNO的缺点 研究显示,当HFNO的流量过大时,如60 L/min,可能导致患者鼻干燥、鼻出血、喉咙痛、头痛,甚至引起胃胀[14,25]。此外,HFNO需要特殊的设备及耗材,在很多地方医院难以普及,可限制其广泛使用。同时,HFNO长时间或高流量使用时的氧气消耗量大,易造成资源的浪费。

2.3.3 HFNO的流量与氧浓度选择 HFNO的使用需要调节流量,而高流量可带给患者不适。国内研究显示,进行HFNO时使用30~35 L/min的低流速设置可有效改善患者氧合和舒适度[26]。目前,关于HFNO流量及氧浓度的最佳选择尚无统一标准。大多数研究中,初始流量通常设置为50~60 L/min,随后根据患者耐受性和血氧饱和度进行调整[27]。氧浓度方面,一般初始设为1.0,而后逐渐下调吸入氧分数,以维持血氧饱和度在92%以上[23]。今后仍需开展更多研究以优化HFNO的参数设置。

2.4 无创通气(noninvasive ventilation, NIV)

2.4.1 NIV的生理效应和临床应用 NIV是使用无创呼吸机通过不同接口和不同的通气方式(如持续正压通气)给患者维持氧合的一项技术[28]。NIV可增加气道压力,改善动脉氧合,增加呼气末肺容积,并通过减少左心室后负荷和右心室前负荷增强心功能,最终减少吸气和呼吸的做功,且可降低AHRF患者的气管插管率[29-30]。

2.4.2 NIV的缺点 NIV的使用伴随鼻漏、口干、压疮、漏气、患者-呼吸机不同步,以及低氧性呼吸衰竭患者产生自己造成的肺损伤等不良反应[31]。NIV的使用需要一定经验,其操作较复杂。此外,NIV氧疗的失败率较高。研究显示,NIV对AHRF患者的治疗失败率达50%,常导致最终插管治疗[32-33]。

2.4.3 NIV的压力的选择 多中心试验显示,高呼气末正压通气组(10~15 cmH2O)的NIV失败率(32%)显著低于低呼气末正压通气组(5 cmH2O)的43%[34]。因此在NIV期间使用高呼气末正压通气可能降低AHRF患者的治疗失败率,但目前此方面研究较少,仍需进一步实验证明。

3 氧疗效果的评估工具

呼吸频率氧合(respiratory rate oxygenation,ROX)指数是重症监护病房和住院环境中AHRF患者HFNO成功的可靠预测指标[35]。研究显示,ROX指数的最佳截断值估计为4.88[36]。在Cox比例风险模型中,经鼻高流量氧疗12 h后测得的ROX指数 ≥4.88与机械通气风险降低显著相关。ROX指数对新发急性呼吸衰竭患者的NIV失败具有中等预测能力[37]。

ROX指数评分的评估维度相对单一,仅纳入氧合参数与呼吸频率。研究显示,整合血流动力学指标(如平均动脉压、乳酸水平)或影像学特征(如肺部实变范围)可提升其预测效能[38]。研究进一步证实,使用肺部超声结合ROX指数能更准确地预测重症监护病房外接受NIV治疗患者的失败风险[39]。因此,多模态评估策略可能成为今后临床实践的重要方向。

4 俯卧位通气在AHRF中的应用

俯卧位通气是一种通过将患者从仰卧位转变为俯卧位进行通气的治疗方法,主要用于改善患者的氧合和呼吸功能。一项meta分析显示,清醒俯卧位通气可有效降低AHRF患者的插管率,但不能缩短患者住院时间,且对病死率的影响有待进一步验证。患者俯卧位时最常见的不良反应为不适和疼痛,其依从性受到影响。建议今后应开展高质量研究,旨在强化清醒俯卧位通气护理管理,提高患者依从性和治疗成功率[40]。研究纳入85例患者参与调查,患者每日清醒俯卧位时间为4(2,6)h,其中依从性好的患者30例(35.3%),清醒俯卧位通气最常见的阻碍因素分别为未及时更换体位以缓解俯卧位的不适(63.5%)、对俯卧位通气治疗意义的认识不足(42.4%)、对疾病恢复缺乏信心(27.1%);logistic回归分析显示,疼痛程度是患者清醒俯卧位通气依从性的影响因素(P<0.05),即疼痛越明显,俯卧位实施情况越差[41]。因此,临床团队应高度重视AHRF患者清醒俯卧位通气的依从性现状,制订针对性的改善策略,以减轻患者不适、提高耐受性,从而提升整体治疗效果。

5 新技术的应用及精准氧疗

5.1 闭环控制系统

闭环控制系统是一种基于患者实时数据反馈的自动化调节系统,通过监测患者的血氧饱和度、动脉血氧分压等指标,能在无需人工干预的情况下自动调整氧气流量和氧浓度,从而实现个体化精准氧疗,确保患者维持在理想的氧合水平。该系统可减少医护人员手动调节的频率,降低工作强度,同时减少人为操作误差。闭环系统实时监测并响应患者的生理状态变化,特别适用于病情波动较大且长时间进行氧疗的AHRF患者,能有效预防低氧或过度氧疗的风险。目前,闭环控制系统已在多种呼吸支持设备中推广,如HFNO和NIV,为氧疗的自动化和精准化提供新可能。研究显示,闭环氧气控制可改善中、重度AHRF患者在接受HFNO治疗时的氧气输送,增加在最佳氧合范围内的时间百分比,并减轻医护人员的工作负担[42]。闭环氧气控制在接受IMV治疗的AHRF小儿患者中,可增强氧气疗法,实现更高效的氧气使用。这项技术还可减少手动调整的必要,可能减轻医疗提供者的工作负担[43]。

5.2 人工智能

人工智能有潜力为呼吸衰竭患者个性化机械通气策略[44]。通过数据分析和机器学习模型提供个性化治疗方案,提升患者的治疗效果和安全性。基于机器学习算法,人工智能可根据患者的年龄、病情严重程度、合并症等因素,为每例患者生成个性化的氧疗方案。人工智能模型可基于患者的历史数据和实时监测信息,预测病情进展及其可能预后。在高危AHRF患者中,人工智能的预测分析可帮助医师制订更早期的干预措施,提高患者预后。如Villar等[45]研究使用机器学习与传统方法相结合,构建预测机械通气治疗的AHRF患者重症监护病房死亡的模型,其研究风险建模识别6个重症监护病房死亡的主要预测因素,包括患者年龄及24 h后的呼气末正压通气、吸入氧分数、平台压、潮气量和肺外器官衰竭数量。可在诊断后24 h内进行预测,识别高危因素以预防重症监护病房患者的死亡。此外,人工智能还可识别患者氧疗失败的风险。最近开发了一种基于机器学习的模型,可为临床医师提供更准确的HFNO结果的早期预测[46]。综上所述,新技术发展将继续推动AHRF领域的发展,最终实现AHRF患者的精准氧疗。

6 小结

AHRF的治疗在近年来取得显著进展,但仍面临一定的局限性。当前氧疗策略包括IMV、HFNO和NIV等,这些技术在改善患者氧合的同时各有局限性。随着ROX指数、俯卧位通气等评估和治疗方法的推广应用,以及闭环控制系统、人工智能等新技术的引入,AHRF的精准化氧疗水平显著提升。然而,如何优化个体化氧疗策略、降低并发症发生率、提高治疗成功率仍是今后研究的重点方向。

展望未来,AHRF的治疗需要从以下3个方面进行突破:①进一步开发动态评估工具,整合多模态参数以提高预测准确性;②加强新技术与传统治疗手段的有机结合,实现治疗方案的精准调整;③通过多学科协作和大数据支持,构建更完善的临床决策系统。随着研究的深入和技术的进步,AHRF患者的生存率和生活质量有望进一步提高,为临床实践提供更有效的治疗选择。

利益冲突声明:所有作者均声明不存在利益冲突。

[参考文献]

[1] Vincent J L,Akça S,De Mendonça A,et al. The epidemiology of acute respiratory failure in critically ill patients [J].Chest,2002,121(5):1602-1609.

[2] Scala R,Heunks L. Highlights in acute respiratory failure [J].Eur Respir Rev,2018,27(147):180008.

[3] Bellani G,Laffey J G,Pham T,et al. Epidemiology,patterns of care,and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries [J]. JAMA,2016,315(8):788-800.

[4] Ferguson N D,Pham T,Gong M N. How severe COVID-19 infection is changing ARDS management [J]. Intensive Care Med,2020,46(12):2184-2186.

[5] Helms J,Catoire P,Abensur Vuillaume L,et al. Oxygen therapy in acute hypoxemic respiratory failure:guidelines from the SRLF-SFMU consensus conference [J]. Ann Intensive Care,2024,14(1):140.

[6] Piraino T. Noninvasive respiratory support in acute hypoxemic respiratory failure [J]. Respir Care,2019, 64(6):638-646.

[7] Xia J,Zhang Y,Ni L,et al. High-flow nasal oxygen in coronavirus disease 2019 patients with acute hypoxemic respiratory failure:a multicenter,retrospective cohort study [J].Crit Care Med,2020,48(11):e1079-e1086.

[8] Papazian L,Aubron C,Brochard L,et al. Formal guidelines:management of acute respiratory distress syndrome [J]. Ann Intensive Care,2019,9(1):69.

[9] Ling R R,Ponnapa Reddy M,Subramaniam A,et al. Epidemiology of acute hypoxaemic respiratory failure in Australian and New Zealand intensive care units during 2005-2022. A binational,registry-based study [J]. Intensive Care Med,2024:50(11):1861-1872.

[10] Jaber S,Citerio G,Slutsky A S. Acute respiratory failure and mechanical ventilation in the context of the COVID-19 pandemic:why a special issue in ICM? [J]. Intensive Care Med,2020,46(12):2131-2132.

[11] Abrams D,Schmidt M,Pham T,et al. Mechanical ventilation for acute respiratory distress syndrome during extracorporeal life support. Research and practice [J]. Am J Respir Crit Care Med,2020,201(5):514-525.

[12] Xie C,Tang W,Leng J,et al. Impacts of initial ICU driving pressure on outcomes in acute hypoxemic respiratory failure:a MIMIC-Ⅳ database study [J]. Sci Rep,2024,14(1):28767.

[13] Von Düring S,Liu K,Munshi L,et al. The association between mechanical power within the first 24 hours and ICU mortality in mechanically ventilated adult patients with acute hypoxemic respiratory failure:a registrybased cohort study [J]. Chest,2025,168(4):901-911.

[14] Rochwerg B,Einav S,Chaudhuri D,et al. The role for high flow nasal cannula as a respiratory support strategy in adults:a clinical practice guideline [J]. Intensive Care Med,2020,46(12):2226-2237.

[15] Wang J C,Peng Y,Dai B,etal. Comparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients:a systematic review and meta-analysis [J]. Ther Adv Respir Dis,2024,18:17534666231225323.

[16] Drake M G. High-flow nasal cannula oxygen in adults:an evidence-based assessment [J]. Ann Am Thorac Soc,2018,15(2):145-155.

[17] Parke R L,Bloch A,Mcguinness S P. Effect of very-highflow nasal therapy on airway pressure and end-expiratory lung impedance in healthy volunteers [J]. Respir Care,2015, 60(10):1397-1403.

[18] Renda T,Corrado A,Iskandar G,et al. High-flow nasal oxygen therapy in intensive care and anaesthesia [J]. Br J Anaesth,2018,120(1):18-27.

[19] Delorme M,Bouchard P A,Simon M,et al. Effects of high-flow nasal cannula on the work of breathing in patients recovering from acute respiratory failure [J]. Crit Care Med,2017,45(12):1981-1988.

[20] Mauri T,Turrini C,Eronia N,et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure [J]. Am J Respir Crit Care Med,2017,195(9):1207-1215.

[21] Mauri T,Alban L,Turrini C,et al. Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure:effects of increasing flow rates [J]. Intensive Care Med,2017,43(10):1453-1463.

[22] Andino R,Vega G,Pacheco S K,et al. High-flow nasal oxygen reduces endotracheal intubation:a randomized clinical trial [J]. Ther Adv Respir Dis,2020,14:1753466620956459.

[23] Ospina-Tascón G A,Calderón-Tapia L E,García A F,et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe covid-19:a randomized clinical trial [J]. JAMA,2021,326(21):2161-2171.

[24] Frat J P,Thille A W,Mercat A,et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure [J]. N Engl J Med,2015,372(23):2185-2196.

[25] Zhang W,Yuan X,Shen Y,et al. Optimal flow of highflow nasal cannula oxygenation to prevent desaturation during sedation for bronchoscopy:a randomized controlled study [J]. Ther Adv Respir Dis,2024,18:17534666241246637.

[26] 周建珍,张传来,徐莉,等. 经鼻高流量氧疗不同流速设置对急性低氧性呼吸衰竭患者的影响[J]. 中华护理杂志,2022,57(15):1797-1803.

[27] Grieco D L,Menga L S,Cesarano M,et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure:the HENIVOT randomized clinical trial [J]. JAMA,2021,325(17):1731-1743.

[28] Grieco D L,Patel B K,Antonelli M. Helmet noninvasive support in hypoxemic respiratory failure [J]. Intensive Care Med,2022,48(8):1072-1075.

[29] Macintyre N R. Physiologic effects of noninvasive ventilation [J]. Respir Care,2019,64(6):617-628.

[30] Rosà T,Menga L S,Tejpal A,et al. Non-invasive ventilation for acute hypoxemic respiratory failure,including COVID-19 [J]. J Intensive Med,2023,3(1):11-19.

[31] Roy A,Khanna P,Chowdhury S R,et al. The impact of high-flow nasal cannula vs other oxygen delivery devices during bronchoscopy under sedation:a systematic review and meta-analyses [J]. Indian J Crit Care Med,2022,26(10):1131-1140.

[32] Carrillo A,Gonzalez-Diaz G,Ferrer M,et al. Noninvasive ventilation in community-acquired pneumonia and severe acute respiratory failure [J]. Intensive Care Med,2012,38(3):458-466.

[33] Thille A W,Contou D,Fragnoli C,et al. Non-invasive ventilation for acute hypoxemic respiratory failure:intubation rate and risk factors [J]. Crit Care,2013,17(6):R269.

[34] Duan J,Liu X,Shu W,et al. Low versus high positive end expiratory pressure in noninvasive ventilation for hypoxemic respiratory failure:a multicenter randomized controlled trial [J]. Intensive Care Med,2025,51(5):861-869.

[35] Ruangsomboon O,Jirathanavichai S,Phanprasert N,et al.Ratio of oxygen saturation to inspired oxygen,ROX index,modified ROX index to predict high flow cannula success in COVID-19 patients:multicenter validation study [J]. West J Emerg Med,2023,24(3):511-521.

[36] Roca O,Messika J,Caralt B,et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure:the utility of the ROX index [J]. J Crit Care,2016,35:200-205.

[37] Duan J,Yang J,Jiang L,et al. Prediction of noninvasive ventilation failure using the ROX index in patients with de novo acute respiratory failure [J]. Ann Intensive Care,2022,12(1):110.

[38] Kansal A,Ong W J D,Dhanvijay S,et al. Comparison of ROX index (SpO2/FIO2 ratio/respiratory rate) with a modified dynamic index incorporating PaO2/FIO2 ratio and heart rate to predict high flow nasal cannula outcomes among patients with acute respiratory failure:a single centre retrospective study [J]. BMC Pulm Med,2022,22(1):350.

[39] Nova A,Rezoagli E,Eronia N,et al. Prognostic performance of bedside lung ultrasound score (LUSS) and ROX index in hypoxemic respiratory failure due to COVID-19 [J]. Diagnostics(Basel),2023,13(7):1361.

[40] 李丝静,江智霞,杨晓玲,等. 清醒俯卧位通气在急性低氧性呼吸衰竭患者中应用效果的meta分析[J]. 中华护理杂志,2023,58(13):1640-1647.

[41] 侯进,潘文彦,刘霄,等. 急性低氧性呼吸衰竭患者清醒俯卧位通气依从性现状分析[J]. 中国护理管理,2024,24(6):862-867.

[42] Roca O,Caritg O,Santafé M,et al. Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen:a randomized cross-over study (the HILOOP study) [J].Crit Care,2022,26(1):108.

[43] Atakul G,Ceylan G,Sandal O,et al. Closed-loop oxygen usage during invasive mechanical ventilation of pediatric patients (CLOUDIMPP):a randomized controlled crossover study [J]. Front Med(Lausanne),2024,11:1426969.

[44] Gallifant J,Zhang J,Del Pilar Arias Lopez M,et al. Artificial intelligence for mechanical ventilation:systematic review of design,reporting standards,and bias [J]. Br J Anaesth,2022,128(2):343-351.

[45] Villar J,González-Martín J M,Fernández C,et al. Early prediction of ICU mortality in patients with acute hypoxemic respiratory failure using machine learning:the MEMORIAL study [J]. J Clin Med,2025,14(5):1711.

[46] Yu H,Saffaran S,Tonelli R,et al. Machine learning models compared with current clinical indices to predict the outcome of high flow nasal cannula therapy in acute hypoxemic respiratory failure [J]. Crit Care,2025,29(1):101.

Research progress on oxygen therapy of acute hypoxemic respiratory failure

DUAN Yongbo1 QI Hongzhi2 SONG Yujing2 YAN Wenjun1▲

1.The First Clinical Medical College, Lanzhou University, Gansu Province, Lanzhou 730000, China; 2.the First Clinical Medical College, Gansu University of Chinese Medicine, Gansu Province, Lanzhou 730000, China

[Abstract] Acute hypoxemic respiratory failure (AHRF) is a common critical condition in clinical practice,characterized by complex pathophysiological mechanisms, and high mortality rate. In recent years, innovations and optimizations in oxygen therapy techniques have significantly improved clinical prognosis of patients with AHRF. This article systematically reviews research progress in major oxygen therapy modalities, including high-flow nasal oxygen,non-invasive positive pressure ventilation, and invasive mechanical ventilation, focuses on analyzing indications,clinical advantages, and potential risks of various technologies. Meanwhile, exploring application value of respiratory rate oxygenation index in efficacy evaluation, as well as development prospects of emerging technologies such as prone position ventilation, closed-loop control system, and artificial intelligence in precision oxygen therapy. By integrating existing evidence, the aim is to provide evidence-based support for clinical physicians to develop personalized oxygen therapy plans, and to point out technological innovation directions and clinical translation challenges that future research needs to focus on.

[Key words] Acute hypoxemic respiratory failure; Non-invasive oxygen therapy; High-flow nasal oxygen; Precision oxygen therapy; Artificial intelligence

[中图分类号] R563

[文献标识码] A

[文章编号] 1673-7210(2026)09(c)-0173-05

DOI:10.20047/j.issn1673-7210.26011101

[基金项目] 甘肃省联合科研基金重点项目(25JRRA1199)。

[作者简介] 段永博(1999.7-),男,硕士;研究方向:危重症患者的氧疗。

▲通信作者

(收稿日期:2026-01-16)

(修回日期:2026-04-20)

X